EyePoint Pharmaceuticals, Inc. — Director's Dealing 2021

Nov 3, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2021-11-01

Reporting Person: Duker Jay S. (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5657.00	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (right to buy)	$31.70	2026-09-26	Common Stock (4000.00)		Direct
Employee Stock Option (right to buy)	$26.50	2029-02-21	Common Stock (4000.00)		Direct
Employee Stock Option (right to buy)	$19.50	2028-06-21	Common Stock (2666.00)		Direct
Employee Stock Option (right to buy)	$13.13	2031-02-09	Common Stock (60300.00)		Direct
Employee Stock Option (right to buy)	$12.90	2030-02-28	Common Stock (3350.00)		Direct
Employee Stock Option (right to buy)	$7.20	2030-07-13	Common Stock (25000.00)		Direct
Restricted Stock Units	$		Common Stock (14900.00)		Direct

Footnotes

F1: This option became fully exercisable on 12/12/2019

F2: This option became fully exercisable on 2/21/2020

F3: This option became fully exercisable on 6/21/2019.

F4: The option to purchase will vest and become exercisable over a four year period as follows: 25% on 2/9/2022 and then ratably over the remaining thirty-six months

F5: This option became fully exercisable on 2/28/2021

F6: The option to purchase will vest and become exercisable as follows: 25% at 7/13/2021 and the remainder ratably, on a monthly basis, over the remaining three years.

F7: The restricted stock units will vest in three ratable annual installments beginning February 9, 2022.